Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 20;9:1011732. doi: 10.3389/fnut.2022.1011732

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Corrêa, Castro, Moser, Ferreira, Quesniaux, Vinolo and Ryffel.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of butyrate in idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by an extracellular matrix (ECM) composed by collagen in a TGF-β dependent way. In this condition the alveolar architecture is compromised, leading to decreased lung compliance, disrupted gas exchange, and respiratory failure. TGF-β alters the metabolism and induces pulmonary fibroblasts differentiation, lowering their mitochondrial NADH, NADH/NAD, and ATP levels, as well as oxidative phosphorylation activity. Butyrate acts as a potent antifibrotic factor, restoring mitochondrial activity, and affecting myofibroblast differentiation. TGF-β, transforming growth factor beta; NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide + hydrogen; ATP, adenosine 5’-triphosphate.